Akari Therapeutics announces interm CEO employment contract

Akari Therapeutics, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel’s employment compensation. Dr Patel’s employment contract reaffirms his desire to align his success directly with the success of the company’s shareholders. Dr. Patel will be compensated solely with equity, aligning his interests with Akari’s shareholders. Dr. Patel’s employment contract includes no cash compensation, severance package or performance bonuses. Dr. Patel believes this compensation arrangement demonstrates transparency and his commitment to enhancing shareholder value. In his leadership role, Dr. Patel remains focused on completing the merger between Akari Therapeutics and Peak Bio to create a robust, diversified pipeline addressing significant unmet medical needs in oncology and inflammation.